Mavrilimumab

DRUG6 trials

Sponsors

Kiniksa Pharmaceuticals, Ltd., Ospedale San Raffaele, The Cleveland Clinic, Kiniksa Pharmaceuticals International, plc, Virginia Commonwealth University

Conditions

ARDS, HumanAcute Respiratory FailureCOVIDCOVID 19COVID-19Covid-19Giant Cell ArteritisPneumonia

Phase 2

KPL-301 for Subjects With Giant Cell Arteritis

CompletedNCT03827018

Kiniksa Pharmaceuticals, Ltd.Giant Cell Arteritis

Start: 2018-09-20End: 2020-11-25Updated: 2023-10-23

Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)

Ospedale San RaffaeleAcute Respiratory Failure, ARDS, Human, Covid-19 +2

Start: 2020-05-22End: 2020-11-22Target: 50Updated: 2020-05-26

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

CompletedNCT04399980

The Cleveland ClinicCOVID 19, Pneumonia, SARS-CoV 2

Start: 2020-05-20End: 2021-04-23Updated: 2021-05-13

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

CompletedNCT04447469

Kiniksa Pharmaceuticals International, plcCOVID

Start: 2020-07-28End: 2022-01-14Updated: 2025-01-22

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

CompletedNCT04463004

Virginia Commonwealth UniversityCOVID-19, Pneumonia, Sars-CoV2

Start: 2020-09-02End: 2020-11-30Updated: 2021-08-11

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

CompletedNCT04492514

Kristin HudockCOVID 19, Pneumonia, SARS-CoV 2

Start: 2020-05-20End: 2020-11-16Updated: 2024-12-09

Related Papers

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.

2022-03-0975 citations

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.

2021-03-1753 citations

473 Mavrilimumab, a human monoclonal antibody targeting GM-CSFRα, inhibits polarization to myeloid-derived suppressor cells (MDSCs) that express PD-L1 and restores T-cell proliferation in vitro

Regular and Young Investigator Award Abstracts2020-11-011 citations

Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study)

Clinical Cardiology2020-08-2448 citations